Gilead Sciences (GILD) Leerink Global Healthcare Conference 2026 summary

HIV strategy and pipeline

• Focus on long-acting HIV treatments, including six-month injectable regimens using lenacapavir with bNAbs or integrase inhibitors, aiming to address unmet needs for patients not virologically suppressed or undiagnosed.

• GS-3242 selected as the preferred integrase inhibitor for combination with lenacapavir, with dose escalation studies targeting four- to six-month dosing intervals.

• Sunlenca 12-month PrEP formulation is in development, with a model-based regulatory path and data readout expected in 2027, aiming for patient availability in 2028.

Expansion in liver disease and Livdelzi

• Livdelzi has demonstrated efficacy in PBC, with ongoing growth in the inadequately responding patient segment.

• The phase III IDEAL study targets incomplete responders, potentially doubling the addressable patient population if successful.

• Early data and similar biology support confidence in expanding Livdelzi to earlier lines of therapy.

Business development and acquisitions

• Recent Arcellx acquisition seen as financially attractive, with expectations for EPS accretion by 2028 and significant commercial opportunity for anito-cel in multiple myeloma.

• Strategy includes both partnerships and direct acquisitions, leveraging deep knowledge and timing to maximize shareholder value.

• Cell therapy franchises, including anito-cel and antibody drug conjugates, are viewed as long-term growth drivers due to manufacturing complexity and durability.